BioCentury | Feb 22, 2020
Product Development

Regenerative medicine for hearing loss makes quiet progress

While the late-stage programs for hearing loss are designed to protect cells in the inner ear, or help them recover from trauma, a growing number of early-stage therapies is aiming for a more dramatic outcome...
BioCentury | Jan 25, 2019
Clinical News

AbbVie's Imbruvica misses pancreatic cancer endpoints

AbbVie Inc. (NYSE:ABBV) said Imbruvica ibrutinib missed the co-primary endpoints in the double=blind, international Phase III RESOLVE (PCYC-1137) trial as part of a first-line combination treatment of metastatic pancreatic cancer. In 424 patients, Imbruvica plus...
BioCentury | Dec 14, 2018
Clinical News

Netris' NTN1 inhibitor safe in Phase I for solid tumors

Netris Pharma S.A.S. (Lyon, France) said escalating doses of up to 20 mg/kg IV NP137 every two weeks were well tolerated with no dose-limiting toxicities (DLTs) reported in a Phase I trial in 19 patients...
BioCentury | Dec 7, 2018
Clinical News

AbbVie's Rova-T suffers another setback in SCLC

AbbVie Inc. (NYSE:ABBV) said on Dec. 5 that it will stop enrollment in the Phase III TAHOE trial of Rova-T rovalpituzumab tesirine as second-line treatment of advanced or metastatic small cell lung cancer after the...
BioCentury | Nov 16, 2018
Clinical News

Blueprint reports 84% ORR for avapritinib in PDGFRα D842V-driven GIST

Blueprint Medicines Corp. (NASDAQ:BPMC) reported updated data from the Phase I NAVIGATOR trial showing that oral avapritinib led to an objective response rate (ORR) of 84% in 56 evaluable patients with PDGFRα D842V-driven advanced gastrointestinal...
BioCentury | Nov 16, 2018
Clinical News

Nektar makes case for NKTR-214 optimism

On a Nov. 10 call with investors, Nektar Therapeutics (NASDAQ:NKTR) and a PI for the Phase I/II PIVOT-2 trial highlighted differences in patient demographics that could be critical for NKTR-214 plus Opdivo nivolumab to achieve...
BioCentury | Oct 26, 2018
Clinical News

Clovis' Rubraca leads to 44% ORR in Phase II for CRPC

Clovis Oncology Inc. (NASDAQ:CLVS) said twice-daily oral Rubraca rucaparib led to a confirmed objective response rate (ORR) by investigator assessment of 44% in 25 evaluable patients with a BRCA1/2 mutation in the Phase II TRITON2...
BioCentury | Oct 11, 2018
Clinical News

Rival RET inhibitor data highlighted at thyroid meeting

Loxo Oncology Inc. (NASDAQ:LOXO) and Blueprint Medicines Corp. (NASDAQ:BPMC) each reported updated data at the American Thyroid Association meeting in Washington from clinical trials evaluating their respective ret proto-oncogene (RET) inhibitors to treat RET-altered cancers....
BioCentury | Sep 14, 2018
Clinical News

Novocure planning submission for TTFields in mesothelioma

Novocure Ltd. (NASDAQ:NVCR) reported final data from the Phase II STELLAR trial to treat previously untreated unresectable malignant pleural mesothelioma showing that its Tumor Treating Fields (TTFields) plus standard of care (SOC) chemotherapy significantly improved...
BioCentury | Jul 17, 2018
Clinical News

Cellectar's CLR 131 reduces tumor burden by 94% in patient with Waldenström's macroglobulinemia

Cellectar Biosciences Inc. (NASDAQ:CLRB) said a patient with advanced Waldenström's macroglobulinemia receiving CLR 131 in a Phase II trial achieved a 94% reduction in tumor burden and complete resolution in four of five targeted tumor...
Items per page:
1 - 10 of 249